Management of stress in inflammatory bowel disease: A therapeutic option?

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 6, 2009, Pages 661-679

  Goodhand, James R ^b   Wahed, Mahmood ^b   Rampton, David S ^a,b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antidepressant; Cognitive behavioral therapy; Crohn's disease; Education; Exercise; Hypnotherapy; Inflammatory bowel disease; Psychological stress; Psychotherapy; Ulcerative colitis

Indexed keywords

AMFEBUTAMONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DESIPRAMINE; GLUCOCORTICOID RECEPTOR; IMIPRAMINE; MELANOCORTIN; MINERALOCORTICOID RECEPTOR; PAROXETINE; PLACEBO; PROOPIOMELANOCORTIN; STEROID; UROCORTIN II; UROCORTIN III;

ALTERNATIVE MEDICINE; ANXIETY; AUTOGENIC TRAINING; CLINICAL TRIAL; COGNITIVE THERAPY; COLITIS; COPING BEHAVIOR; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE TITRATION; ENTERITIS; EXERCISE; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPNOSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTESTINE INNERVATION; LIFESTYLE MODIFICATION; MAJOR DEPRESSION; MEDITERRANEAN DIET; MENTAL STRESS; MOOD DISORDER; NONHUMAN; PARASYMPATHETIC INNERVATION; PREVALENCE; PSYCHOANALYSIS; PSYCHODYNAMICS; PSYCHOEDUCATION; PSYCHOTHERAPY; RELAPSE; RELAXATION TRAINING; REVIEW; SELF CARE; SOCIAL SUPPORT; STRESS MANAGEMENT; THERAPY EFFECT; ULCERATIVE COLITIS;

ANIMALS; ANTIDEPRESSIVE AGENTS; DISEASE MODELS, ANIMAL; HUMANS; HYPNOSIS; INFLAMMATORY BOWEL DISEASES; MOOD DISORDERS; PSYCHOTHERAPY; RATS; STRESS, PSYCHOLOGICAL;

EID: 73449138789     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.55     Document Type: Review

References (136)

1. Chrousos GP, Kino T. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10(2), 213-219 (2007).
2. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat. Rev. 5(3), 243-251 (2005).
3. McEwen BS. Protective and damaging effects of stress mediators. N. Engl. J. Med. 338(3), 171-179 (1998).
4. Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 16(5), 300-317 (2009).
5. Selye H. A syndrome produced by diverse nocuous agents. Nature 138, 32 (1936).
6. Selye H. Stress and the general adaptation syndrome. Br. Med. J. 1(4667), 1383-1392 (1950).
7. Selye H. Stress without distress. JB Lippincott, NY, USA (1974).
8. Lazarus RS, Deese J, Osler SF. The effects of psychological stress upon performance. Psychol. Bull. 49, 293 (1952).
9. Lazarus RS. From psychological stress to the emotions: a history of changing outlooks. Annu. Rev. Psychol. 44, 1-21 (1993).
10. Folkman S, Moskowitz JT. Coping: pitfalls and promise. Annu. Rev. Psychol. 55, 745-774 (2004).
11. Taylor SE, Stanton AL. Coping resources, coping processes, and mental health. Annu. Rev. Clin. Psychol. 3, 377-401 (2007).
12. Goodhand J, Rampton D. Psychological stress and coping in IBD. Gut 57(10), 1345-1347 (2008).
13. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 54(10), 1481-1491 (2005).
14. Lightman SL. The neuroendocrinology of stress: a never ending story. J. Neuroendocrinol. 20(6), 880-884 (2008).
15. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 31(9), 464-468 (2008).
16. Mawdsley JE, Rampton DS. The role of psychological stress in inflammatory bowel disease. Neuroimmunomodulation 13(5-6), 327-336 (2006).
17. Saunders PR, Kosecka U, McKay DM, Perdue MH. Acute stressors stimulate ion secretion and increase epithelial permeability in rat intestine. Am. J. Physiol. 267(5 Pt 1), G794-G799 (1994).
18. Castagliuolo I, Lamont JT, Qiu B et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am. J. Physiol. 271(5 Pt 1), G884-G892 (1996).
19. Castagliuolo I, Wershil BK, Karalis K, Pasha A, Nikulasson ST, Pothoulakis C. Colonic mucin release in response to immobilization stress is mast cell dependent. Am. J. Physiol. 274(6 Pt 1), G1094-G1100 (1998).
20. Lenz HJ, Raedler A, Greten H, Vale WW, Rivier JE. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropinreleasing factor. Gastroenterology 95(6), 1510-1517 (1988).
21. Ait-Belgnaoui A, Bradesi S, Fioramonti J, Theodorou V, Bueno L. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 113(1-2), 141-147 (2005).
22. Demaude J, Salvador-Cartier C, Fioramonti J, Ferrier L, Bueno L. Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: implications for delayed epithelial barrier dysfunction. Gut 55(5), 655-661 (2006).
23. Mazzon E, Sturniolo GC, Puzzolo D, Frisina N, Fries W. Effect of stress on the paracellular barrier in the rat ileum. Gut 51(4), 507-513 (2002).
24. Ponferrada A, Caso JR, Alou L et al. The role of PPARg on restoration of colonic homeostasis after experimental stressinduced inflammation and dysfunction. Gastroenterology 132(5), 1791-1803 (2007).
25. Saunders PR, Hanssen NP, Perdue MH. Cholinergic nerves mediate stress-induced intestinal transport abnormalities in Wistar-Kyoto rats. Am. J. Physiol. 273(2 Pt 1), G486-G490 (1997).
26. Santos J, Saunders PR, Hanssen NP et al. Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am. J. Physiol. 277(2 Pt 1), G391-G399 (1999).
27. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 134(2), 577-594 (2008).
28. Chen C, Brown DR, Xie Y, Green BT, Lyte M. Catecholamines modulate Escherichia coli O157:H7 adherence to murine cecal mucosa. Shock 20(2), 183-188 (2003).
29. Green BT, Lyte M, Kulkarni-Narla A, Brown DR. Neuromodulation of enteropathogen internalization in Peyer's patches from porcine jejunum. J. Neuroimmunol. 141(1-2), 74-82 (2003).
30. Caso JR, Leza JC, Menchen L. The effects of physical and psychological stress on the gastro-intestinal tract: lessons from animal models. Curr. Mol. Med. 8(4), 299-312 (2008).
31. Soderholm JD, Yang PC, Ceponis P et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 123(4), 1099-1108 (2002).
32. Soderholm JD, Yates DA, Gareau MG, Yang PC, MacQueen G, Perdue MH. Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress. Am. J. Physiol. 283(6), G1257-G1263 (2002).
33. Velin AK, Ericson AC, Braaf Y, Wallon C, Soderholm JD. Increased antigen and bacterial uptake in follicle associated epithelium induced by chronic psychological stress in rats. Gut 53(4), 494-500 (2004).
34. Boudry G, Jury J, Yang PC, Perdue MH. Chronic psychological stress alters epithelial cell turn-over in rat ileum. Am. J. Physiol. 292(5), G1228-G1232 (2007).
35. Aberg KM, Radek KA, Choi EH et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J. Clin. Invest. 117(11), 3339-3349 (2007).
36. Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol. 1(Suppl. 1), S67-S74 (2008).
37. Varghese AK, Verdu EF, Bercik P et al. Antidepressants attenuate increased susceptibility to colitis in a murine model of depression. Gastroenterology 130(6), 1743-1753 (2006).
38. Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 56(11), 1522-1528 (2007).
39. Gue M, Bonbonne C, Fioramonti J et al. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Am. J. Physiol. 272(1 Pt 1), G84-G91 (1997).
40. + lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat. Med. 5(10), 1178-1182 (1999).
41. Collins SM, McHugh K, Jacobson K et al. Previous inflammation alters the response of the rat colon to stress. Gastroenterology 111(6), 1509-1515 (1996).
42. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM. Reactivation of inf lammatory bowel disease in a mouse model of depression. Gastroenterology 136(7), 2280-2288; e2281-e2284 (2009). Depression in mice can cause a reactivation of experimental colitis that can be prevented by desmethylimipramine and appears to be mediated by inhibition of the vagal anti-inflammatory pathway acting through nicotinic acetylcholine receptors.
43. Ghia JE, Blennerhassett P, Collins SM. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J. Clin. Invest. 118(6), 2209-2218 (2008).
44. Farhadi A, Keshavarzian A, Van de Kar LD et al. Heightened responses to stressors in patients with inflammatory bowel disease. Am. J. Gastroenterol. 100(8), 1796-1804 (2005).
45. Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 131(2), 410-419 (2006).
46. Maunder RG, Greenberg GR, Nolan RP, Lancee WJ, Steinhart AH, Hunter JJ. Autonomic response to standardized stress predicts subsequent disease activity in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 18(4), 413-420 (2006).
47. Li J, Norgard B, Precht DH, Olsen J. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark. Am. J. Gastroenterol. 99(6), 1129-1133 (2004).
48. Salem SN, Shubair KS. Non-specific ulcerative colitis in Bedouin Arabs. Lancet 1(7488), 473-475 (1967).
49. Wood JD, Peck OC, Tefend KS et al. Colitis and colon cancer in cotton-top tamarins (Saguinus oedipus oedipus) living wild in their natural habitat. Dig. Dis. Sci. 43(7), 1443-1453 (1998).
50. North CS, Alpers DH. A review of studies of psychiatric factors in Crohn's disease: etiologic implications. Ann. Clin. Psychiatry 6(2), 117-124 (1994).
51. North CS, Alpers DH, Helzer JE, Spitznagel EL, Clouse RE. Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann. Intern. Med. 114(5), 381-386 (1991).
52. Moser G, Maier-Dobersberger T, Vogelsang G, Lochs H. Inflammatory bowel disease (IBD): patients' beliefs about the etiology of their disease - a controlled study. Psychsom. Med. 88(6), 419-422 (1993).
53. North CS, Clouse RE, Spitznagel EL, Alpers DH. The relation of ulcerative colitis to psychiatric factors: a review of findings and methods. Am. J. Psychiatry 147(8), 974-981 (1990).
54. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr. Mol. Med. 8(4), 247-252 (2008).
55. Bernstein CN, Walker JR, Graff LA. On studying the connection between stress and IBD. Am. J. Gastroenterol. 101(4), 782-785 (2006).
56. Keefer L, Keshavarzian A, Mutlu E. Reconsidering the methodology of "stress" research in inflammatory bowel disease. J. Crohn's Colitis 2(3), 193-201 (2008). Reviews the difficulties associated with the study of psychological stress in inflammatory bowel disease (IBD), which provides user-friendly guidelines regarding how to conduct clinical trials in this field.
57. Bitton A, Dobkin PL, Edwardes MD et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 57(10), 1386-1392 (2008). First study to show the influence of coping strategies on the course of Crohn's disease. Provides an indirect pointer to one of the mechanisms by which cognitive-behavioral therapy might work, and highlights the importance of measuring not only the degree of psychological stress but also the pateints coping style.
58. Bitton A, Sewitch MJ, Peppercorn MA et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am. J. Gastroenterol. 98(10), 2203-2208 (2003).
59. Deter HC, von Wietersheim J, Jantschek G, Burgdorf F, Blum B, Keller W. High-utilizing Crohn's disease patients under psychosomatic therapy. Biopsychosoc. Med. 2(1), 18 (2008).
60. Duffy LC, Zielezny MA, Marshall JR et al. Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav. Med. 17(3), 101-110 (1991).
61. Levenstein S, Prantera C, Varvo V et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am. J. Gastroenterol. 95(5), 1213-1220 (2000).
62. Mardini HE, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig. Dis. Sci. 49(3), 492-497 (2004).
63. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Holtmann. GJ, Andrews JM. Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: an observational cohort prospective study. Biopsychosoc. Med. 2, 11 (2008).
64. Mittermaier C, Dejaco C, Waldhoer T et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom. Med. 66(1), 79-84 (2004).
65. Persoons P, Vermeire S, Demyttenaere K et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment. Pharmacol. Ther. 22(2), 101-110 (2005).
66. Vidal A, Gomez-Gil E, Sans M et al. Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am. J. Gastroenterol. 101(4), 775-781 (2006).
67. Riley SA, Mani V, Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 31(2), 179-183 (1990).
68. Bernstein C, Singh S, Graff L, Walker J, Cheang M. A prospective population based study of triggers of flare of IBD. In: DDW. Chicago (2009).
69. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 455(7215), 894-902 (2008).
70. Kurina LM, Goldacre MJ, Yeates D, Gill LE. Depression and anxiety in people with inflammatory bowel disease. J. Epidemiol. Community Health 55(10), 716-720 (2001).
71. Walker JR, Ediger JP, Graff LA et al. The Manitoba IBD cohort study: a populationbased study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am. J. Gastroenterol. 103(8), 1989-1997 (2008).
72. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, HoltmAnn. GJ. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm. Bowel Dis. 13(2), 225-234 (2007).
73. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 24(3), 190-192 (1983).
74. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig. Dis. Sci. 49(3), 469-474 (2004).
75. Barratt HS, Kalantzis C, Polymeros D, Forbes A. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Aliment. Pharmacol. Ther. 21(2), 141-147 (2005).
76. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am. J. Gastroenterol. 97(2), 389-396 (2002).
77. Graff LA, Walker JR, Lix L et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin. Gastroenterol. Hepatol. 4(12), 1491-1501 (2006).
78. Robertson DA, Ray J, Diamond I, Edwards JG. Personality profile and affective state of patients with inflammatory bowel disease. Gut 30(5), 623-626 (1989).
79. Lix LM, Graff LA, Walker JR et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm. Bowel Dis. 14(11), 1575-1584 (2008).
80. Goodhand JR, Wahed M, Farmer AD, Mawdsley JE, Aziz Q, Rampton DS. Are mood disorders more common in patients with active than inactive inflammatory bowel disease? Presented at: United European Gastroenterology Week. London, UK. 25 November 2009.
81. Goehler LE, Lyte M, Gaykema RP. Infection-induced viscerosensory signals from the gut enhance anxiety: implications for psychoneuroimmunology. Brain Behav. Immun. 21(6), 721-726 (2007).
82. Ait-Belgnaoui A, Eutamene H, Houdeau E, Bueno L, Fioramonti J, Theodorou V. Lactobacillus farciminis treatment attenuates stress-induced overexpression of Fos protein in spinal and supraspinal sites after colorectal distension in rats. Neurogastroenterol. Motil. 21(5), 567-573; e518-e569 (2009).
83. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. 9(1), 46-56 (2008).
84. Miehsler W, Weichselberger M, Offerlbauer-Ernst A et al. Which patients with IBD need psychological interventions? A controlled study. Inflamm. Bowel Dis. 14(9), 1273-1280 (2008).
85. Davison GC, Neale JM, Kring AM. Abnormal Psychology. Wiley, NJ, USA (2004).
86. Johnston EC, Cunningham Owens DG, Lawrie SM, Sharpe M, Freeman CPL (Eds). Companion to Psychiatric Studies. Churchill Livingstone, NY, USA (2004).
87. O'Connor JF, Daniels G, Flood C, Karush A, Moses L, Stern LO. An Evaluation of the effectiveness of psychotherapy in the treatment of ulcerative colitis. Ann. Intern. Med. 60, 587-602 (1964).
88. Jantschek G, Zeitz M, Pritsch M et al. Effect of psychotherapy on the course of Crohn's disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's Disease. Scand. J. Gastroenterol. 33(12), 1289-1296 (1998).
89. Keller W, Pritsch M, Von Wietersheim J et al. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the German Prospective Multicenter Psychotherapy Treatment study on Crohn's Disease. J. Psychosom. Res. 56(6), 687-696 (2004).
90. Deter HC, Keller W, von Wietersheim J et al. Psychological treatment may reduce the need for healthcare in patients with Crohn's disease. Inflamm. Bowel Dis. 13(6), 745-752 (2007).
91. Maunder RG, Esplen MJ. Supportiveexpressive group psychotherapy for persons with inf lammatory bowel disease. Can. J. Psychiatr. 46(7), 622-626 (2001).
92. Milne B, Joachim G, Niedhardt J. A stress management programme for inflammatory bowel disease patients. J. Adv. Nurs. 11(5), 561-567 (1986).
93. Schwarz SP, Blanchard EB. Evaluation of a psychological treatment for inflammatory bowel disease. Behav. Res. Ther. 29(2), 167-177 (1991).
94. Mussell M, Bocker U, Nagel N, Olbrich R, Singer MV. Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural treatment: exploratory study of effectiveness. Scand. J. Gastroenterol. 38(7), 755-762 (2003).
95. Garcia-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn's disease. Behav. Res. Ther. 42(4), 367-383 (2004).
96. Elsenbruch S, Langhorst J, Popkirowa K et al. Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother. Psychosom. 74(5), 277-287 (2005).
97. Langhorst J, Mueller T, Luedtke R et al. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up. Scand. J. Gastroenterol. 42(6), 734-745 (2007).
98. Diaz Sibaja M, Comeche Moreno M, Mas Hesse B. Protocolized cognitive-bevioural therapy for inflammatory bowel disease. Revista Espanola de Enfermedades Digestivas, 99(10), 593-598 (2007).
99. Wahed M, Corser M, Goodhand JR, Rampton DS. Does psychological counselling alter the natural history of inflammatory bowel disease? Inflamm. Bowel Dis. Accepted for publication (2009).
100. Szigethy E, Kenney E, Carpenter J et al. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J. Am. Acad. Child Adolesc. Psychiatry 46(10), 1290-1298 (2007).
101. Szigethy E, Craig AE, Iobst EA et al. Profile of depression in adolescents with inflammatory bowel disease: implications for treatment. Inflamm. Bowel Dis. 15(1), 69-74 (2009).
102. Fowler JH, Christakis NA. Dynamic spread of happiness in a large social network: longitudinal analysis over 20 years in the Framingham Heart Study. BMJ (Clinical research ed.) 337, a2338 (2008).
103. Shepanski MA, Hurd LB, Culton K, Markowitz JE, Mamula P, Baldassano RN. Health-related quality of life improves in children and adolescents with inflammatory bowel disease after attending a camp sponsored by the Crohn's and Colitis Foundation of America. Inflamm. Bowel Dis. 11(2), 164-170 (2005).
104. Larsson K, Sundberg Hjelm M, Karlbom U, Nordin K, Anderberg UM, Loof L. A group-based patient education programme for high-anxiety patients with Crohn disease or ulcerative colitis. Scand. J. Gastroenterol. 38(7), 763-769 (2003).
105. Kennedy AP, Nelson E, Reeves D et al. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 53(11), 1639-1645 (2004).
106. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol, 19(4), 235-244 (2005).
107. Bregenzer N, Lange A, Furst A, Gross V, Scholmerich J, Andus T. Patient education in inflammatory bowel disease does not influence patients knowledge and long-term psychosocial well-being. Z. Gastroenterol. 43(4), 367-371 (2005).
108. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1), 28-40 (2006).
109. Walker EA, Gelfand MD, Gelfand AN, Creed F, Katon WJ. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen. Hosp. P Psychiatry 18(4), 220-229 (1996).
110. Kane S, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology 125(4), 1290 (2003).
111. Kast RE, Altschuler EL. Remission of Crohn's disease on bupropion. Gastroenterology 121(5), 1260-1261 (2001).
112. Esmaeili A, Masjedi M, Ani A et al. New insights of anti-depressant therapy in the management of ulcerative colitis Gastroenterology 134(4, Suppl 1), A-100 (2008).
113. Ford AC, Marwaha A, Lim A, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and metaanalysis. Gut 58(3), 367-378 (2009).
114. Verdu B, Decosterd I, BuClin. T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs 68(18), 2611-2632 (2008).
115. Ewer TC, Stewart DE. Improvement in bronchial hyper-responsiveness in patients with moderate asthma after treatment with a hypnotic technique: a randomised controlled trial. BMJ 293(6555), 1129-1132 (1986).
116. Friedman H, Taub HA. The use of hypnosis and biofeedback procedures for essential hypertension. Int. J. Clin. Experiment. Hypnosis 25(4), 335-347 (1977).
117. Horne DJ, White AE, Varigos GA. A preliminary study of psychological therapy in the management of atopic eczema. British J. Med. Psychology 62 (Pt 3), 241-248 (1989).
118. Langewitz W, Izakovic J, Wyler J, Schindler C, Kiss A, Bircher AJ. Effect of self-hypnosis on hay fever symptoms - a randomised controlled intervention study. Psychother. Psychosom. 74(3), 165-172 (2005).
119. Shertzer CL, Lookingbill DP. Effects of relaxation therapy and hypnotizability in chronic urticaria. Arch. Dermatol. 123(7), 913-916 (1987).
120. Whorwell PJ. Review article: the history of hypnotherapy and its role in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 22(11-12), 1061-1067 (2005).
121. Colgan SM, Faragher EB, Whorwell PJ. Controlled trial of hypnotherapy in relapse prevention of duodenal ulceration. Lancet 1(8598), 1299-1300 (1988).
122. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 123(6), 1778-1785 (2002).
123. Jones H, Cooper P, Miller V, Brooks N, Whorwell PJ. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut 55(10), 1403-1408 (2006).
124. Mawdsley JE, Jenkins DG, Macey MG, Langmead L, Rampton DS. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am. J. Gastroenterol. 103(6), 1460-1469 (2008).
125. Shetty A, Kalantzis C, Polymeros D, Vega R, Abraham S, Forbes AGA. Hypnotherapy for inflammatory bowel disease- a randomised, placebo-controlled trial. Gut 53 (2004).
126. Keefer L, Keshavarzian A. Feasibility and acceptability of gut-directed hypnosis on inflammatory bowel disease: a brief communication. Int. J. Clin. Experiment. Hypnosis 55(4), 457-466 (2007).
127. Miller V, Whorwell PJ. Treatment of inflammatory bowel disease: a role for hypnotherapy? Int. J. Clin. Experiment Hypnosis 56(3), 306-317 (2008).
128. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. Cochrane Database Syst. Rev. (4), CD004366 (2008).
129. Loudon CP, Corroll V, Butcher J, Rawsthorne P, Bernstein CN. The effects of physical exercise on patients with Crohn's disease. Am. J. Gastroenterol. 94(3), 697-703 (1999).
130. Ng V, Millard W, Lebrun C, Howard J. Low-intensity exercise improves quality of life in patients with Crohn's disease. Clin. J. Sport Med. 17(5), 384-388 (2007).
131. Maunder R, Esplen MJ. Facilitating adjustment to inflammatory bowel disease: a model of psychosocial intervention in non-psychiatric patients. Psychother. Psychosom. 68(5), 230-240 (1999). Introducing the concept of a biopsychosocial model in IBD, which emphasizes the importance of adopting an individualized approach to psychological treatments based on the stage of adjustment of the patient to their disease.
132. Zareie M, Johnson-Henry K, Jury J et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 55(11), 1553-1560 (2006).
133. Ait-Belgnaoui A, Han W, Lamine F et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 55(8), 1090-1094 (2006).
134. Santos J, Benjamin M, Yang PC, Prior T, Perdue MH. Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells. Am. J. Physiol. 278(6), G847-G854 (2000).
135. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP, and clinical indices. Am. J. Gastroenterol. 103(1), 162-169 (2008).
136. Maunder RG, Greenberg GR, Hunter JJ, Lancee WJ, Steinhart AH, Silverberg MS. Psychobiological subtypes of ulcerative colitis: pANCA status moderates the relationship between disease activity and psychological distress. Am. J. Gastroenterol. 101(11), 2546-2551 (2006).